CASE REPORT
Successful treatment of infliximab-induced psoriasiform skin lesions despite biologic therapy intensification in a paediatric patient with Crohn’s disease and primary sclerosing cholangitis
1
Department of Paediatrics, Gastroenterology and Nutrition, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland
Submission date: 2021-02-01
Final revision date: 2021-02-25
Acceptance date: 2021-03-12
Publication date: 2021-07-01
Pediatr Pol 2021;96(2):143-147
KEYWORDS
TOPICS
ABSTRACT
Therapy with infliximab (IFX), a tumour necrosis factor-α (TNF-α) inhibitor, has been demonstrated to be highly effective in several immune-mediated inflammatory diseases including Crohn’s disease (CD) and psoriasis, both in adult and paediatric patients. With the increasingly widespread use and longer follow-up of IFX, one unexpected adverse effect that has been reported is the occurrence of psoriasis-like lesions, mainly during the maintenance therapy. The present report was aimed at describing a new case of IFX-induced psoriasis-like lesions in a 17-year-old boy with CD and primary sclerosing cholangitis (PSC), which was successfully treated with topical agents, despite IFX therapy intensification due to loss of the clinical response.
REFERENCES (29)
1.
Osamura A, Suzuki Y. Fourteen-year anti-TNF therapy in Crohn’s disease patients: clinical characteristics and predictive factors. Dig Dis Sci 2018; 63: 204-208.
2.
Church PC, Guan J, Walters TD, et al. Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn’s disease. Inflamm Bowel Dis 2014; 20: 1177-1186.
3.
Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe crohn’s disease in children. Gastroenterology 2007; 132: 863-873.
4.
De Bie CI, Hummel TZ, Kindermann A, et al. The duration of effect of infliximab maintenance treatment in paediatric Crohn’s disease is limited. Aliment Pharmacol Ther 2011; 33: 243-250.
5.
Van Rheenen H, Van Rheenen PF. Long-term efficacy of anti-tumor necrosis factor agents in pediatric luminal Crohn’s disease: A systematic review of real-world evidence studies. Pediatr Gastroenterol Hepatol Nutr 2020; 23: 121-131.
6.
Eligius Hellström A, Färkkilä M, Kolho K-L. Infliximab-induced skin manifestations in patients with inflammatory bowel disease. Scand J Gastroenterol 2016; 51: 563-571.
7.
Bae JM, Lee HH, Lee BI, et al. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study. Aliment Pharmacol Ther 2018; 48: 196-205.
8.
Bassukas I, Gaitanis G, Katsanos K, et al. Psoriasis and inflammatory bowel disease: links and risks. Psoriasis Targets Ther 2016; 6: 73-92.
9.
Mylonas A, Conrad C. Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon. Front Immunol 2018; 9: 2746.
10.
Conrad C, Di Domizio J, Mylonas A, et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun 2018; 9: 1-11.
11.
Fania L, Morelli M, Scarponi C, et al. Paradoxical psoriasis induced by TNF-α blockade shows immunological features typical of the early phase of psoriasis development. J Pathol Clin Res 2020; 6: 55-68.
12.
Stoffel E, Maier H, Riedl E, et al. Analysis of anti-tumour necrosis factor-induced skin lesions reveals strong T helper 1 activation with some distinct immunological characteristics. Br J Dermatol 2018; 178: 1151-1162.
13.
Weizman AV, Sharma R, Afzal NM, et al. Stricturing and fistulizing Crohn’s disease is associated with anti-tumor necrosis factor-induced psoriasis in patients with inflammatory bowel disease. Dig Dis Sci 2018; 63: 2430-2438.
14.
Palmela C, Peerani F, Castaneda D, et al. Inflammatory bowel disease and primary sclerosing cholangitis: a review of the phenotype and associated specific features. Gut Liver 2017; 12: 17-29.
15.
Mälkönen T, Wikström A, Heiskanen K, et al. Skin reactions during Anti-TNFα therapy for pediatric inflammatory bowel disease: a 2-year prospective study. Inflamm Bowel Dis 2014; 20: 1309-1315.
16.
Romiti R, Araujo KM, Steinwurz F, et al. Anti-tumor necrosis factor α-related psoriatic lesions in children with inflammatory bowel disease: Case report and systematic literature review. Pediatr Dermatol 2016; 33: 174-178.
17.
Eickstaedt JB, Killpack L, Tung J, et al. Psoriasis and psoriasiform eruptions in pediatric patients with inflammatory bowel disease treated with anti-tumor necrosis factor alpha. Agents Pediatr Dermatol 2017; 34: 253-260.
18.
Shivaji UN, Sharratt CL, Thomas T, et al. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2019; 49: 664-680.
19.
Courbette O, Aupiais C, Viala J, et al. Infliximab paradoxical psoriasis in a cohort of children with inflammatory bowel disease.
21.
Barthel C, Biedermann L, Frei P, et al. Induction or exacerbation of psoriasis in patients with crohn’s disease under treatment with anti-TNF antibodies. Digestion 2014; 89: 209-215.
22.
Li SJ, Perez-Chada LM, Merola JF. TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management. Journal of Psoriasis and Psoriatic Arthritis 2019; 4: 70-80.
23.
Iborra M, Beltrán B, Bastida G, et al. Infliximab and adalimumab-induced psoriasis in Crohn’s disease: A paradoxical side effect.
25.
Mocci G, Marzo M, Papa A, et al. Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. J Crohn’s Colitis 2013; 7: 769-779.
26.
Fu Y, Lee CH, Chi CC. Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatology 2018; 154: 1417-1427.
27.
Sherlock ME, Walters T, Tabbers MM, et al. Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms.
29.
Seneschal J, Milpied B, Vergier B, et al. Cytokine imbalance with increased production of interferon-α in psoriasiform eruptions associated with antitumour necrosis factor-α treatments. Br J Dermatol 2009; 161: 1081-1088.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
